U.S. drugmakers' quest for tax-friendly foreign addresses could get waylaid by the Treasury Department's efforts to end corporate inversions. The inversions, which involve U.S.-based multinationals moving their tax residence overseas to take advantage of more favorable corporate tax rates, have become a popular theme in the pharmaceutical industry over the past few years, with several companies acquiring addresses in Ireland. Read More
SHANGHAI – After a 15-month corruption investigation, the verdict for Glaxosmithkline plc in China has been guilty as charged, surprising few industry insiders. It is routine for the government to come out on top in such high-profile cases, while most readily admit there are no saints in China's downstream pharmaceutical business. Read More
DUBLIN – Shares in DBV Technologies SA gained more than 20 percent Tuesday on positive news from a phase IIb trial of the company's Viaskin Peanut allergy treatment. Read More
BOSTON – With autoimmune/anti-inflammatory agents abounding, biotech firms may be hard pressed to develop competitive drugs, but the market still is worth going after and big pharma is willing to pay for therapies that can help the wide sector of nonresponders. Read More
LONDON – Europe's current model of drug development and approval is not appropriate for breakthrough products based on the latest advances in genomics and new understanding of human biology coming up the chain, according to a new report by academic researchers at the Dutch public institute TI Pharma. Read More
TG Therapeutics Inc., of New York, is exercising an early option to buy exclusive global rights to TGR-1202, a phosphoinositide-3-kinase (PI3K)-delta inhibitor, from its partner, Rhizen Pharmaceuticals SA. Read More
Siteone Therapeutics Inc., incubated at Janssen Labs – Johnson & Johnson's external R&D hub – took a step toward independence by completing its initial equity financing. Read More
Dermira Inc., of Redwood City, Calif., sets terms for its initial public offering (IPO), upsizing the potential raise, including overallotments, to $98.4 million from its initial filing for $75 million by offering 5.35 million shares priced in a range of $14 to $16. Read More
Novavax Inc., of Gaithersburg, Md., said the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) exercised the option period in its current contract to continue development of the company's recombinant seasonal and pandemic influenza vaccines. Read More
Acceleron Pharma Inc., of Cambridge, Mass., reported interim results from a two-part study sponsored by the Gynecology Oncology Group testing dalantercept as a monotherapy in patients with recurrent or persistent epithelial ovarian cancer. Read More
